DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

Information source: Cunningham, Derek N., O.D., P.A.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Phase: N/A

Status: Recruiting

Sponsored by: Cunningham, Derek N., O.D., P.A.

Official(s) and/or principal investigator(s):
Derek Cunningham, OD, Principal Investigator, Affiliation: Dell Laser Consultants

Overall contact:
Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com

Summary

The purpose of this study is to evaluate the comfort of BEPREVE compared to LASTACAFT after instillation.

Clinical Details

Official title: A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis

Study design: Observational Model: Case Control, Time Perspective: Prospective

Detailed description: After one drop is instilled subjects will complete a comfort assessment at 1, 3, 5, and 10 minutes after drop instillation.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study:

1. Are male or female at least 18 years of age who are diagnosed with allergic conjunctivitis.

2. Have allergic ocular symptoms within the last three days.

3. Are willing/able to follow instructions from the study investigator and his/her staff.

4. Have signed informed consent approved by Institutional Review Board or Independent Ethics Committee.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study:

1. Have known hypersensitivity to either BEPREVE™ or LASTACAFT® or to any component of the test article (including "procedural" medications such as anesthetic and/or fluorescein drops, dilating drops, etc.).

2. Have active corneal pathology noted in the study eye at the screening visit. Active corneal pathology is defined as corneal pathology that is non stable, or greater than mild, or will compromise assessment of the safety or efficacy of treatment.

3. Are pregnant or nursing/lactating.

Locations and Contacts

Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com

Derek Cunningham, 901 S. Mopac Expy, Bldg. 4, Suite 350, Texas 78746, United States; Recruiting
Derek Cunningham, OD, Phone: 512.347.0255, Email: dcunningham@dellvision.com
Additional Information

Starting date: April 2011
Last updated: April 19, 2011

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014